Why PBM transparency rules aren’t enough to lower drug prices
House lawmakers recently passed a health care bill that grabbed headlines for what it excluded: a solution to the looming expiration of enhanced Affordable Care Act tax credits. But largely overlooked inside the bill was a provision that did make it through, a long-requested provision toward creating stronger federal legislation directly targeting pharmacy benefit managers (PBMs), the middlemen who increasingly determine what Americans pay for their medications. These rules …
